Medical Oncology

Uzm. Dr. Harun Muğlu

Doctor and researcher Bağcılar Eğitim ve Araştırma Hastanesi İstanbul
Lung NeoplasmsCarcinoma, Non-Small-Cell LungNeoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Lung Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Carcinoma, Non-Small-Cell Lung 2 publications
  • Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionBağcılar Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workLung NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications59 publicationsOpenAlexFrom source
  • ORCID0000-0001-9584-0827ORCIDFrom source
  • Last synchronised5 November 2026 08:55https://bagcilareah.saglik.gov.tr/TR-1478518/doktorlarimiz.html#harun-muglusaglik.gov.tr

Scientific work

Publications on Lung Neoplasms

59 publications

  1. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Open-access full textSource: OpenAlex

  2. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Open-access full textSource: OpenAlex

  3. Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

    Medicina, 2026

    DOI 10.3390/medicina62112136 Open-access full textSource: OpenAlex

  4. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062406 PMID 41899326 Open-access full textSource: OpenAlex

  5. Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    Pharmaceuticals, 2026

    DOI 10.3390/ph19040587 PMID 42075843 Open-access full textSource: OpenAlex

  6. A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15083118 PMID 42074920 Open-access full textSource: OpenAlex

  7. Predictive and Prognostic Value of Androgen Receptor Expression Across All Molecular Subtypes in Patients with Breast Cancer Who Received Neoadjuvant-Treatment: Single-Center Retrospective Analysis

    Breast Cancer Targets and Therapy, 2026

    DOI 10.2147/bctt.s647399 PMID 42936308 Open-access full textSource: OpenAlex

  8. Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    OncoImmunology, 2026

    DOI 10.1080/2162402x.2026.2738262 PMID 42788839 Open-access full textSource: OpenAlex

  9. Real-world Efficacy and Safety of Trastuzumab Deruxtecan in HER2-positive Metastatic Breast Cancer: A Multicenter Retrospective Study from Türkiye

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-1-1 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  10. Unveiling the Uncommon: A Comprehensive Review and Case Report on Targeting Rare MET Fusions in NSCLC

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-7-10 Open-access full textSource: OpenAlex

View all 59 publications